Interleukin-40 as a biomarker of mortality risk in patients with severe pneumonia - Top-Institutions - MDSpire

Interleukin-40 as a biomarker of mortality risk in patients with severe pneumonia

  • By

  • Hong Tan

  • Hanyi Wang

  • Xuanyi Zhou

  • Jun Duan

  • Xiaoliang Yang

  • May 28, 2026

  • 0 min

Share

Top Institutions in Pulmonary

Brief introduction explaining scope and methodology.

  • #1

    The First Affiliated Hospital of Chongqing Medical University
    The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing

    Key Differentiators

    • Pulmonology

  • #2

    Peking Union Medical College Hospital
    Peking Union Medical College Hospital

    Beijing, Beijing

    Key Differentiators

    • Pulmonology

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Pulmonology

  • #4

    University Hospital Düsseldorf
    University Hospital Düsseldorf

    Düsseldorf, North Rhine-Westphalia

    Key Differentiators

    • Pulmonology

  • #5

    Taipei Veterans General Hospital
    Taipei Veterans General Hospital

    Taipei, Taipei

    Key Differentiators

    • Pulmonology

Original Source(s)

Interleukin-40 as a biomarker of mortality risk in patients with severe pneumonia

  • by Hong Tan, Hanyi Wang, Xuanyi Zhou, Jun Duan, Xiaoliang Yang

  • May 28, 2026

Related Content

AARC Statement on RT Overnight Coverage

Insights into epidemiological and clinical burden of bronchiolitis among hospitalized children: a call for preventive interventions

Clinical efficacy and safety of different video-assisted thoracoscopic surgery approaches for bullous lung resection: a systematic review and meta-analysis